A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse
Risk stratification tools are frequently used to help guide treatment decisions after first relapse in multiple myeloma. Researchers have developed a new risk stratification tool consisting of 4 distinct dimensions that is used to characterize survival expectations.
Daratumumab, Bortezomib, Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated Efficacy Analysis of CASTOR
By prior treatment exposure, all subgroups in the CASTOR trial benefited from the addition of daratumumab to bortezomib/dexamethasone, including patients refractory to lenalidomide at last treatment.
Leslie Lauersdorf discusses her perceptions regarding daratumumab therapy and identifies how her patients have benefited from this treatment option.
Leslie Lauersdorf addresses the different questions her patients ask her when they begin daratumumab therapy.
Leslie Lauersdorf explains why it's so important to understand the patient's baseline to help manage side effects.
Leslie Lauersdorf has seen the Janssen CarePath Program help alleviate some of the financial burden of treatment for her patients.
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
Recent data indicate that daratumumab can further decrease minimal residual disease burden when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.
Meta-Analysis to Compare Efficacy of Treatment Regimens for Patients with Relapsed/Refractory Multiple Myeloma
Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma.
Results of an Early Access Treatment Protocol of Daratumumab in US Patients with Relapsed or Refractory Multiple Myeloma
An early access study confirms the safety and preservation of health-related quality of life of daratumumab in multiple myeloma.
Potentiation of Antimyeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide, or Bortezomib via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP
Combinations of targeted agents that include daratumumab offer synergy to alter the tumor microenvironment to promote the efficacy of these combinations in the treatment of multiple myeloma.